Skip to main content
Smaller Larger Print

MENU

Myeloid Gene Panel

Requires patient informed consent

Sample Reqs

Aor bone marrow aspirate sample

Turnaround

2 weeks

Special instructions

No special instructions.



Sample type guide

A

Lavender Vacutainer, EDTA anticoagulant, 3ml minimum

Test details

This next-generation sequencing (NGS) panel enables the analysis of 75 genes that are frequently mutated in myeloid malignancies. With its expanded gene coverage, plus identification of copy number variations (CNVs), the panel provides more detailed information than other panels as well as further genomic information.

The 75 genes are related to acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS). It also contains a number of targets that are related to lymphoid malignancies (acute lymphocytic leukemia, ALL, and lymphoma), and 23 of the genes are also targeted for the detection of CNVs.

Among the targets are Calreticulin (CALR), JAK2, MPL and NPM1, which were previously offered as individual tests.

 

ABL1, ANKRD26, ASXL1, ATRX, BCOR, BCORL1, BRAF BTK, CALR, CBL, CBLB, CBLC, CCND2, CDKN2A, CEBPA, CSF3R, CUX1, CXCR4, DCK, DDX41,, DHX15, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, MYC, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RBBP6, RUNX1, SETBP1, SF3B1, SH2B3, SLC29A1, SMC1A SMC3, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, U2AF2, WT1, XPO1, ZRSR2.
Myeloid gene panel (75 genes)
Additional information

Last-updated: 13/03/23

 

Back to test list